2
Table of Contents
• China – A Tremendous Opportunity
- Market Overview
- Cross Border Transactions
• About Ventac Partners
- Global Business
- Portfolio Companies
- China Business
• The Ventac Team
• Ventac’s Track Record – Life Science Transactions
• Ventac’s China Venture Capital Relationships
• Summary - Why China? Why Ventac?
• Appendix
- Examples of Cross-Border Transactions
- Shanghai Partner Bio
- Global Partners

33
China - Tremendous Opportunity
• Life Science in China is Booming –
– China’s life science industry has been
growing at approximately 10-20% per year.
– #1 market in the world by 2020
– Massive government incentives
– Large pool of returnees that have come
back to China to start new businesses
• Cross Border Deal Activity is Strong -
– More than 85% of all partnerships in China
over the last several years.
– 90% cross border in 2015
– Flow of technology primarily into China
– $1.8B in partnering deals in 2014
– $4.2B in 2015
– 31% preclinical => significant early stage
– Licensing deals: 58%, Co-development: 23%
– Deal terms improving rapidly
• China VCs – Investing in Western Cos.
– VC - $1.7B in 2014, $1.8B in 2015
– Cross border investment is happening
Source: World Bank, IMS, McKinsey, MOFCOM, CASS, CADF, NHFPC, ChinaBio

4
China – Massive Government Support
• Chinese government committed $125
billion for health care reforms:
• Expanding insurance coverage
• Improving healthcare systems
• Promoting universal coverage
• The 12th Five Year Plan (‘11-’15) dedicated 33%
of total budget to healthcare spending
• Traditional Chinese Medicine products
outnumber NCEs by ~3:1
• Recognized need to shift away from TCM
to more modern, effective treatments
• Recognized need to tackle certain disease
areas, such as infectious disease (both
bacterial and viral), in order to promote
general welfare

5
China – Wide Range of Cross Border Deals
• Venture Capital Investment
• Corporate Investment
• Rx, Dx, Med. Devices, Formulation
• Improving Deal Terms as Competition
Increases
• In-bound
• Out-bound
• Research Institute – Discovery Platform Co.
• Research Institute – CRO
• Chinese Co. – US University
• Chinese Co. – US JV with University
Investment
Licensing &
Partnering
M&A
Drug
Discovery
University
Tech-Trans.
Please see the appendix for specific examples.

66
About Ventac Partners
• Global consulting and transaction company
• Dedicated to life science
• Headquartered in Copenhagen, Denmark
• Grow our own portfolio of startups with several
successful exits to date
• 19 partners in N. America, Europe and Asia
• 7+ years experience in China (via Nine Bridges Capital)
• Experts in Life Science corporate/business development

77
19 Partners and 13 Offices on 3 Continents
Lund
Copenhagen
Basel
Madrid
San Diego
Boulder
Boston
Munich
Trondheim
Düsseldorf
Shanghai
San Francisco
London

88
Ventac’s Global Business
Strategic Partnerships – Buy and Sell Side
- Pharma, SMEs, Tech-Transfer
- All subsectors of Life Science
- Licensing, JVs, M&A, virtually all deal structures
Venture Capital Fundraising
- Rx, Dx, Medical Devices, Healthcare IT
Ventac Portfolio Companies
- Europe, Asia
Market Research
- Analysis of therapeutic/diagnostic/medtech areas in
various territories
- Mapping of companies/products
- Market opportunity assessments
BD&L Training Workshops
- Life Science Executives
- University Post-graduates / Post-Docs / Tech Transfer
8

9
• Spin out from Norwegian UST & Oslo University
• Focuses on chronic inflammatory disorders. Currently in Phase
II for psoriasis. Preclinical development programs in
glomerulonephritis and rheumatoid arthritis
• Partnering discussions ongoing
• Spin-out from the Biomedical Centre (BMC) at Lund University,
Sweden
• Developing a tolerogenic vaccine – a unique treatment concept
for inducing immune tolerance.
• Orphan designation by the EMA
• Currently in pre-clinical development
• Listing on stock exchange in Sweden in June 2015

10
• Spin-out from the Norwegian University of Science
and Technology, Norway, dedicated to develop novel
anti-cancer agents targeting DNA repair and cell
cycle control
• Currently in CTA/IND-stage
• Recently completed series B financing round
• Spin-out from AMC, Holland, developing novel
treatments for immune mediated and
neurogenerative disorders
• Currently in late pre-clinical development
• Recently completed series B financing round

1111
• Spin-out from the Cancer Research Foundation in
Denmark
• Currently develops a therapeutic vaccine against
NSCLC; will enter phase I clinical testing in 2017
• Listed in the stock exchange in Sweden in 2016
• Swiss company based on a technology licensed
from the Hellenic Pasteur Institute, Greece.
• Currently in pre-clinical development with an
antibody against extracellular hsp90 target
• Looking for Series A funding

12
Ventac’s China Business
Strategic Partnerships – Buy and Sell Side
- Pharma, SMEs, Tech-Transfer
- Licensing, JVs, M&A, virtually all deal structures
Venture Capital Fundraising
- Rx, Dx, Medical Devices, Healthcare IT

13
Ventac’s China Team
• Ventac Partners currently has
19 partners and 13 offices
across North America,
Europe, and Asia
• All with previous industry
experience in strategy and
operations, executive and
non executive management,
and/or extensive fund
raising, business
development and deal
making track records
• Partners brought into a
project as needed, including
potentially a full turn-around
or M&A team, enabling
Ventac to efficiently scale up
or down as needed
• Mikael Oerum – Copenhagen
• Founder, Ventac Partners
• Current CEO, Avexxin
• Board Chair, HUNT Biosciences, others
• Jonathan Myers – Shanghai
• Former BD, Pain Tx, Onyx, Chiron, Roche
• Numerous transactions worldwide
• Expert in Life Science Valuation
• BSc., Chemical Engineering
• MBA, Rotterdam SOM, Erasmus Univ.
• Randy Berholtz – San Diego
• General Counsel to ACON Group from
Hangzhou
• Extensive China fundraising experience
• Venture Capital COO and Senior Advisor
• Experience in partnering in the pharma,
device and Dx fields field in China
• Extensive knowledge of Chinese IP, law and
litigation

14
• Melya Hughes Crameri, PhD – London
• Strategic Advisor to numerous US &
European life science companies
• Previously Founder & CEO of Evolva Inc.
& EVP Evolva SA (EVE.SW - $50M risk
capital raised and $80M non-dilutive)
• Extensive experience in negotiation
• Neil Thomas – Madrid & London
• 19 years executive and board level
experience in biotech and medtech.
• Investee company experience in 5 VC
funding rounds totaling $117m USD
• PhD, University of Durham, UK
• Joseph Tucker - Boston
• Current CEO, Epimeron
• Former CEO, Taiga Bioactives,
Pharmavation, Stem Cell Therapeutics
• Ph.D. Univ. of Calgary

15
• Dede Willis – Boulder
• 30 years in startups and turnarounds
• Board Member Panion Animal Health AB
• CEO Orbit Genomics (incorporating soon)
• Former Co-founder and COO Boulder
Diagnostics Inc (now Oxford Immunotec)
• Former CEO Proligo Biochemie GmbH
and VP Operations Proligo LLC
• B.Sc. Chemical Engineering, MBA
• Scott Woodward – San Francisco
• 20 years in various Healthcare
Leadership Roles
• Global VP-Biomarker Operations for a US
Headquartered multi-national CRO
• Extensive dealmaking experience in
private equity and pharma

Ventac Partners Global Track Record
Financing * M&A *
$200,000,000
Strategic Alliance &
License
2006
Licensing *
$900,000,000 $380,000,000
2009
$11,500,000
2013
$58,500,000
2010
$500,000,000
2011
$917,000,000
2013
$50,000,000
2006
$450,000,000
Acquisition by
2014
$7,500,000
Merged with
2003
$21,800,000
2013
$348,000,000
2013
$1,800,000,000
2013
License
License
License
License
License
License
License
License
License
License
Series B
2007
2008
$30,000,000
2007
$14,000,000
2012
Series C
F-1 Prepared
2014
Preparation for IPO at
NASDAQ
Dual Track / M&A by
Roche
Series D
$Not disclosed
2007
Co-ownership & License
Professor Imanishi &
Pantheco
$Not disclosed
Acquisition of 8 drugs
2013
This
image c
This
image c
This
image c
$6,700,000
2012
License
$10,000,000
2000
Private Placement to a
consortium of Nordic
Investors
Lead Manager
$13,000,000
2001
Private Placement to a
consortium of Nordic
Investors
Sole Manager
$Not disclosed
2000
Worldwide rights to
LNA technology
$180,000,000
2000
Worldwide semi-exlusive
manufacturing rights to
LNA technology
$Not disclosed
2000
Use of LNA in clinical
diagnostics
€23,000,000
2004
€10,500,000
2006
€17,000,000
2003
Series B
Private Financing
Series C
Private Financing
Private Financing
$400,000,000
2005
Strategic Alliance
&
License
$4,000,000
2014
Series A
$10,300,000
2006
Series A
(2nd
closing)
$47,000,000
2009
Series B
$35,000,000.
2000
Novartis Research
Foundation
Partnership
$Not disclosed
Merged with
2014
$Not disclosed
Acquisition of
2014
$700,000,000
2007
€27,200,000
2007
€27,000,000
2009
Series B Series C
Summary
Licensing Deals - 18 deals done (3 not disclosed), valued at $6.45B+
Financings - 14 deals done (1 not disclosed) valued at $296M+
M&A - 5 deals done (3 not disclosed) valued at $458M+
16

1717
Ventac Partners China Track Record
Closed & Ongoing Deals:
– Funding - $35M raise for private US Rx company from Chinese large pharma.
– Funding - $10M+ raise for Ventac affiliate from large China Dx company
– Funding/Option - $2 million with large Chinese investment company and also provided the
company with an exclusive option for Chinese rights
– M&A – Sold immunoassay business line to US multi-national company for $450 million
– M&A - Purchased a private US pharmaceuticals company with an oncology drug for $25 million
upfront plus over $100 million in milestones
– Co-development – Several R&D collaborations with large international pharma companies worth
over $150 million
– License – License with Swiss pharma company for over $75 million for cell based Dx
– Litigation - Engaged in multi-million dollar international patent litigation
– Distribution – several deals in Dx space
– Clinical trials - arranged multiple site Phase III study in Chinese - female sexual dysfunction
– Ongoing – Term sheet stage with cross border license in wound care space (device)
– Others – Not Closed: Fertility Dx, Cancer Dx, Cancer Rx
China Consulting Projects:
– Valuation of China Rx opportunities in diabetes, breast cancer, NSCLC space
– Evaluation of HK life science ecosystem – HK Government
Details can be shared under confidentiality

18
China VC Relationships
• We maintain an active
database of 100+ life
science investor
relationships
• These firms are on our
“First To Call” List
• Other investors include:
– W.I. Harper
– Mingly China Growth Fund
– DFJ Dragon Fund
– Mustang Ventures
– Mitsui Global Investment

19
PE Relationships & Targets
• Ventac’s China
focused PE
relationships and
targets include the
following.
• Some are PEs, while
others are VC/PE
hybrids
• Some PE investors,
such as Milestone
Capital, will
syndicate PE
investments

20
Why China? Why Ventac?
• The Time for China is Now
– Market is growing, deal terms are improving and China is
hungry for good Western technology
• China is Not Without Risk
– IP theft, unethical business practices, poor manufacturing,
corrupt regulatory/certification processes and fluid rule of law
are typical problems
– Ventac will guide you to work with the best people and
companies
• Ventac Can Help Your Company With Virtually All Cross
Border Transactions in China Life Science
– Experience with just about any deal structure you can imagine,
including VC funding, licensing, joint ventures, M&A,
divestitures tech-transfer agreements, strategic partnerships
and so on
Strong
Demand
Strong
China
Demand
China Is
Complex
Ventac
China
Ventac
Knows
China

21
Ventac Partners
Please Contact Us
Melya Hughes Crameri, Ph.D.
Ventac Partners – London
mcrameri@ventac-partners.com
+44 7415 572 682
Ventac Partners – Shanghai
jmyers@ventac-partners.com
+86 13601989842
+1 (415) 202-3211
Scott Woodward
Ventac Partners – San Francisco
swoodward@ventac-partners.com
+1 (415) 720 5800
Randy Berholtz
Ventac Partners – San Diego
rberholtz@ventac-partners.com
+1 (858) 205-5091

23
Examples of Cross-Border Transactions
• Cross Border Financings:
– Case 1 – VC Investment:
– Investor: Lilly Asia Ventures
– Portfolio Company: Crown Biosciences
– Deal Summary: Crown Bioscience closed a $26.6 million Series D funding round led by
Lilly Asia Ventures Fund II. CrownBio is a preclinical CRO, specializing in oncology and
metabolic disorders, headquartered in California with labs in Beijing, Taicang (China), the
UK and North Carolina. CrownBio said it would use the money to expand its platform
technologies and make acquisitions. (May, 2014)
– Case 2 – VC Investment:
– Investor: BVCF
– Portfolio Company: MicuRx Pharmaceuticals
– Deal Summary: MicuRx Pharmaceuticals, a San Francisco-Shanghai antibiotics company,
raised $25 million in Series B financing (see story). The round was led by BVCF (formerly
BioVeda) and joined by previous investors Morningside Group and Devon Park
Bioventures. The proceeds will be used to fund the US-China development of MRX-I,
which has completed a Phase I clinical trial in China. MRX-1 is a novel oral oxazolidinone
antibiotic that targets drug-resistant infections. (August, 2013)

24
• Cross Border Licensing Deals
– Case 1 – Drug Development:
– Licensee: Zhejiang Hisun, China
– Licensor: Celsion, USA
– Deal Summary: Zhejiang Hisun licensed Thermadox, a liposomal formulation of
doxorubicin for primary liver cancer. Terms included: $5M Option Payment Upfront,
$5M Payment after exercising the Option, $25M License upfront (net $15M after
deducting option payments), $55M in R&D Milestones, $45M in Sales Milestones, Tiered
double digit royalties. (January, 2013)
– Case 2 – Drug Formulation:
– Licensee: Sihuan Pharma, Hong Kong
– Licensor: to-BBB, Netherlands
– Deal Summary: Sihuan to perform feasibility studies on certain of Sihuan’s existing drugs
in to-BBB’s G-Technology® delivery system . If successful, the tests will lead to a
collaborative effort to develop one or more compounds. The G-Technology® - delivery
system allows drugs to cross the blood-brain barrier and, at the same time, facilitates
sustained release of the active ingredients. (December, 2013)

25
• Cross Border Discovery Collaborations:
– Case 1 - Research Institute-CRO:
– Partner 1: Shanghai Institute of Materia Medica (SIMM), China
– Partner 2: Crown Bioscience, USA
– Deal Summary: As a first step, the two entities will build the world’s largest mouse
clinical trial center by combining their collections of patient-derived xenograft (PDX)
models. Then, using Crown’s oncology discovery and translational capabilities, the
center will accelerate development of SIMM’s oncology drug candidates. Crown is a US-
headquartered CRO with its lab operations in China. (November 2013)
– Case 2 – Research Institute-Drug Discovery Company:
– Partner 1: iHuman Institute at ShanghaiTech University, China
– Partner 2: RuiYi, US/China
– Deal Summary: RuiYi, a San Diego-Shanghai innovative drug discovery company, formed
a research collaboration with iHuman Institute at ShanghaiTech University (see story).
The collaboration will use RuiYi's iCAPS technology to create novel monoclonal
antibodies. Ray Stevens, PhD, a structural biologist at San Diego’s Scripps Institute, is the
Founding Director of the iHuman Institute and the Scientific Founder of RuiYi. In
addition, RuiYi announced that it closed a $4 million debt financing from Silicon Valley
Bank. (June, 2014)

26
• Cross Border Mergers & Acquisitions:
– Case 1 - Clinical CRO acquires preclinical CRO:
– Acquirer: Tigermed, China
– Target: Frontage Labs, USA/China
– Deal Summary: Hangzhou Tigermed Consulting (SHE: 300347), a China clinical-stage
CRO, will add pre-clinical capability to its service offerings by paying $50.2 million to
acquire a 70% stake in Frontage Labs, headquartered in Pennsylvania. Frontage Labs
provides both pre-clinical and clinical CRO services through its facilities in Pennsylvania
and the Zhangjiang Hi-Tech Park in Shanghai. Tigermed said Frontage would continue to
operate independently, with its current management team, led by CEO Dr. Song Li,
remaining intact. (May 2014)
– Case 2 – Medical Devices Acquisitions:
– Acquirer: Shanghai Fosun, China
– Targets: Several Israeli Medical Devices Companies
– Deal Summary: Shanghai Fosun Pharma (SHE: 600196; HK: 02196) is planning to acquire
a number of Israeli medical device companies, and has already begun due diligence on
several, according to the company’s CEO, Fang Yao. The news comes one year after
Fosun paid $240 million to acquire Alma Lasers, an Israeli company that makes high-end
wrinkle-smoothing devices. Fosun may incorporate all of its acquired Israeli operations
under Alma, said Yao. (June, 2014)

27
• Cross Border University Collaborations:
– Case 1 - China-USA University Collaboration:
– Company: HD Biosciences, China
– University: Marshall University, USA
– Deal Summary: HD Biosciences, a Shanghai drug development CRO, will partner with
Marshall University of West Virginia to develop innovative treatments for cancer. The
partners will share the costs of discovery and development of the drugs, and they will
also own IP and commercialization rights jointly. The Marshall Institute for
Interdisciplinary Research (MIIR) and the Marshall University Joan C. Edwards School of
Medicine will be HD Biosciences’ partners. (July 2014)
– Case 2 – JV in US to Develop University Technologies:
– Companies: Gloria Pharma, China, Cumberland Pharma, USA
– University: Vanderbilt University, USA
– Deal Summary: Harbin Gloria Pharma (SHE: 002437), a China injectable drugmaker, has
joined Cumberland Pharma (NSDQ: CPIX) of Tennessee in Cumberland Emerging
Technologies, a translational R&D effort. Both companies have made $1 million
investments in CET, though Cumberland remains the majority owner. Gloria will have the
right of first refusal on China rights to CET’s product candidates, which are discovered at
Vanderbilt University in Nashville and other regional research centers. (May, 2014)

28
Ventac Partner Bio - Shanghai
• Jonathan, who has lived and worked on four continents, has 17+ years
experience in VC fundraising as well as phases of pharma/biotech
transactions, from initial screening to due diligence to valuation,
negotiation and closing. This experience includes practically all deal
structures, including in-licensing, out-licensing, joint ventures, and mergers
& acquisitions.
• Prior to Ventac Partners, Jonathan was Founder and Managing Director of
Nine Bridges Capital, a Shanghai based life science financial advisory and
business development consulting firm. Jonathan has also worked in various
business development and corporate finance roles pharma/biotech
industry in the San Francisco Bay Area and in Basel, Switzerland for
companies including Pain Therapeutics, Onyx Pharmaceuticals Chiron
Corporation and Roche. Jonathan worked on over 50 deals during his time
in the Bay Area and accomplishments of note include the completion of a
$400M out-licensing deal as well as various in-licensing deals, drug
formulation deals, manufacturing deals and option agreements. Jonathan
began his pharma/biotech career in a hybrid corporate finance/business
development role, building valuation models in support of deal negotiation
and running the due diligence process for many deals at Chiron
Corporation.
• Prior to receiving his MBA from the Rotterdam School of Management,
Erasmus University, Jonathan was a chemical process engineer with Nobel
Industries (Akzo Nobel), in Sweden, Chile and the United States, having
received is BSc degree in chemical engineering from Michigan State
University.

2929
Mikael
Ørum Martin
Austin
Dede
Willis
Melya Hughes
Crameri
Aarti
KapoorKostas
Alevizopoulos
Bengt
WestrinMirko
Stange
Lars
Hedbys
Peter
Damsbo
Rolf
Ehrnstrom
Robert
Buchanan
Scott
Woodward
Neil
Thomas
Dennis
Henriksen
Pharma – Biotech – Medtech
Jonathan
Myers
Henrik
Stage
Randi
Berholtz
Joe
Tucker
Ventac’s Global Team
Consulting, Startups, Strategic Transactions and Fundraising

Ventac Partners China Business

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Similar to Ventac Partners China Business

Similar to Ventac Partners China Business (20)

Recently uploaded

Recently uploaded (20)

Ventac Partners China Business